Skip to content
Studies have shown that active fund managers routinely underperform the S&P500 index*
Home
Articles
WALL STREET X
Forecasts
Portfolios
Wall Street X
Articles
Forecasts
Portfolios
Search
Results for
{phrase}
(
{results_count}
of
{results_count_total}
)
Displaying
{results_count}
results of
{results_count_total}
SAB Biotherapeutics, Inc. (NASDAQ: SABS)
SABS Stock Predictions and Ratings
WSX Rating:
NOT AVAILABLE
WSX Forecast (1yr):
NOT AVAILABLE
Analyst Rating:
STRONG BUY
Analyst Forecast (1yr):
270.50%
SABS Stock Analysis
SABS
PE Ratio:
SABS
PEG Ratio:
Not Available
SABS
Forward EPS Growth (12 month):
0.00%
SABS
PS Ratio:
SABS
PSG Ratio:
Not Available
SABS
Forward Revenue Growth (12 month):
0.00%
SABS Articles
No data was found